That said, GLP-1 medications for weight loss are not for everyone, and they can cause unpleasant, even serious, side effects, ...

Eli Lilly is currently the leader in the field and still has strong momentum. Novo Nordisk has made some moves that it hopes ...

You’re reading The Checkup With Dr. Wen, a newsletter on how to navigate medical and public health challenges. Click here to ...

The White House may have struck a deal with Eli Lilly and Novo Nordisk last week to lower the costs of their weight loss ...

Novo Nordisk and Eli Lilly reached deals to lower GLP-1 drug costs for Medicare and Medicaid patients under Trump’s new pricing initiative.

Orforglipron is Lilly’s oral GLP-1 in phase 3 development as a treatment for diabetes and obesity. The FDA is expected to approve the drug in March 2026. Lilly’s November news release states that the ...

Facing increased competition in the weight loss market and intense pressure from President Donald Trump, Novo Nordisk announced Monday that it is lowering prices for its blockbuster obesity and ...

The introduction of AbbVie’s hepatitis C drugs in 2014 forced Gilead’s hand in the fight for market dominance in hepatitis C.

President Trump hailed his deal with pharma companies on GLP-1 drug pricing. The question is how big of a difference the deal ...

Senate Democrats are demanding that President Trump release the list of the most recent Medicare-negotiated drug prices.

With new agreements from President Donald Trump promising lower prices on popular weight-loss drugs, the use of GLP-1 ...

The maker of the weight-loss and diabetes drugs Wegovy and Ozempic has cut the prices for most versions of these blockbuster ...